1356017-29-2

Upstream product

• 56926-73-9 trans-3-(3-nitro-4-hydroxyphenyl)-acrylic acid 
• 118509-98-1 (E)-methyl 3-(4-methoxy-3-nitrophenyl)acrylate 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 

Downstream Products

• 1356016-37-9 (E)-3-(3-amino-4-methoxy-phenyl)-prop-2-en-1-ol 
• 875230-36-7 3-(3-amino-4-methoxy-phenyl)-propan-1-ol 
• 1356015-56-9 pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [5-((E)-3-hydroxypropenyl)-2-methoxyphenyl]amide 

Relevant academic research and scientific papers

4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads

Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.